Ainos, Inc. is expanding its Smell AI deployments, powered by AI Nose, into healthcare infrastructure, collaborating with MacKay Memorial Hospital and Topco Scientific Co., Ltd. This move broadens the application of its technology beyond semiconductor and robotics industries. The expansion positions Smell AI as an integral perception layer for environmental monitoring and safety within hospitals, aiming to convert deployments into repeatable revenue streams throughout 2026, which is identified as a key scale-up phase.

State Street reported a higher first-quarter profit of $764 million ($2.49 a share), up from $644 million ($2.04 a share) in the previous year. This increase was driven by strong fee growth, especially from its foreign exchange trading services. The company's revenue also rose by 16% to $3.8 billion for the quarter.

State Street reported strong first-quarter 2026 financial results, with diluted EPS of $2.49 and total revenue of $3.8 billion, a 16% increase year-on-year. The bank achieved record quarterly fee revenue and net interest income, demonstrating broad-based momentum across its key business segments. Despite an AI analyst's "Neutral" rating driven by inconsistent cash flow, the company's solid profitability, improved balance sheet, and supportive valuation suggest a positive outlook.

Wipro Limited reported Q4 FY26 earnings with IT Services revenue at $2.65 billion, a sequential growth of 0.2%, and an operating margin of 17.3%. The company announced a significant share buyback of INR 15,000 crores, the largest in its history. Discussions focused on regional performance, the impact of client-specific issues and delayed large deal ramp-ups in Americas 2, and the strategic pivot towards AI-native business and platforms.

Zions Bancorp (NASDAQ: ZION) is expected to announce its Q1 earnings, with analysts anticipating increased earnings per share and revenue. The article explores how investors can generate $500 monthly from Zions' 2.92% annual dividend yield, requiring an investment of approximately $205,113 (3,333 shares). An analyst recently maintained an "In-Line" rating but lowered the price target to $63 ahead of the earnings release.

KBC Group NV reduced its stake in Apollo Global Management Inc. by 4.4% in the fourth quarter of 2025, selling 10,459 shares. Despite this, other institutions like Mitsubishi UFJ Asset Management Co. Ltd. significantly increased their holdings. Analysts maintain a "Moderate Buy" rating for Apollo, with a consensus price target of $150.75, though the stock faces volatility from potential deals and ongoing litigation.

KBC Group NV reduced its stake in PayPal Holdings, Inc. by 7.8% in Q4, selling 90,175 shares and bringing its total holdings to 1,070,207 shares valued at approximately $62.48 million. This comes amidst mixed analyst ratings, with some trimming price targets and expressing concerns over competition from "X Money" and ongoing legal and strategic uncertainties for PayPal. Insiders have also been selling shares, totaling over $3.8 million in the past three months.

Barclays Bank PLC is offering principal-protected-style Notes linked to NVIDIA Corporation (NVDA) common stock, with an issue date of May 5, 2026, and maturity on November 4, 2027. These Notes offer a capped upside return of 36.82% and a 20% downside buffer, providing positive returns on modest declines in NVIDIA's stock, but exposing investors to losses exceeding the 20% buffer if the final value is significantly lower. The investment involves credit risk of Barclays and is subject to potential U.K. Bail-in Power.

KBC Group NV increased its holdings in Ameriprise Financial, Inc. by 12.2% in the fourth quarter, now owning 150,606 shares valued at $73.85 million. Ameriprise Financial reported strong Q4 results, surpassing earnings and revenue expectations, and offers a quarterly dividend of $1.60. Despite recent insider selling, analysts maintain a "Hold" consensus rating with a target price of $544.22.

KBC Group NV has reduced its stake in Edwards Lifesciences Corporation by 22.4% in the fourth quarter, selling 107,030 shares and now holding 371,758 shares valued at approximately $31.7 million. This reduction comes amidst several other institutional investors increasing their holdings, and company insiders selling shares worth about $7.12 million in the last three months. Edwards Lifesciences missed Q4 EPS expectations but experienced a 13.3% revenue growth, with analysts maintaining a "Moderate Buy" rating for the stock.